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Significance 
Carboxypeptidase O (CPO) is a membrane-anchored brush-border enzyme 
associated with the small intestinal phase of protein digestion with distinctive 
specificity toward acidic C-terminal (C-t) amino acids. The combined activity of 
human CPO (hCPO) and pancreatic carboxypeptidases enables the C-t proteolysis 
of the great majority of amino acids present in dietary proteins. Here we disclose 
mechanism and structures of hCPO, both ligand-free and -bound with a natural 
peptidic inhibitor ascribing the exquisite specificity toward C-t acidic residues to a 
single amino acid, Arg275, in the substrate-binding pocket. Mutations of this residue 
to Asp and Ala suffices to reverse the specificity to C-t basic and hydrophobic 
residues, respectively, and faithfully mirror the specificity variants (hCPB, hCPA1, 
hCPA2) in enzyme kinetic assays. 
 
Abstract 
Human metallocarboxypeptidase O (hCPO) is a recently discovered digestive 
enzyme localized to the apical membrane of intestinal epithelial cells. Unlike 
pancreatic metallocarboxypeptidases, hCPO is glycosylated and produced as an 
active enzyme with distinctive substrate specificity toward C-terminal (C-t) acidic 
residues. Here we present the crystal structure of hCPO at 1.85-Å resolution, both 
alone and in complex with a carboxypeptidase inhibitor (NvCI) from the marine 
snail Nerita versicolor. The structure provides detailed information regarding 
determinants of enzyme specificity, in particular Arg275, placed at the bottom of the 
substrate-binding pocket. This residue, located at “canonical” position 255, where it 
is Ile in human pancreatic carboxypeptidases A1 (hCPA1) and A2 (hCPA2) and Asp 
in B (hCPB), plays a dominant role in determining the preference of hCPO for acidic 
C-t residues. Site-directed mutagenesis to Asp and Ala changes the specificity to C-t 
basic and hydrophobic residues, respectively. The single-site mutants thus faithfully 
mimic the enzymatic properties of CPB and CPA, respectively. hCPO also shows a 
preference for Glu over Asp, probably as a consequence of a tighter fitting of the Glu 
side chain in its S1′ substrate-binding pocket. This unique preference of hCPO, 
together with hCPA1, hCPA2, and hCPB, completes the array of C-t cleavages 
enabling the digestion of the dietary proteins within the intestine. Finally, in addition 
to activity toward small synthetic substrates and peptides, hCPO can also trim C-t 
extensions of proteins, such as epidermal growth factor, suggesting a role in the 
maturation and degradation of growth factors and bioactive peptides. 
 
Metallocarboxypeptidases (MCPs) are important zinc-dependent enzymes that 
cleave single amino acids from the C termini (C-t) of peptides and proteins, and 
participate in a wide range of physiological processes in humans, ranging from 
digestion of dietary proteins to the regulation of blood fibrinolysis and the maturation 
of neuropeptides and hormones, among others (1–3). According to the MEROPS 
database, the most thoroughly studied group of MCPs is the M14 family of proteases 
(4). Based on sequence homologies and structural features, members of this large 
family (about 25 members in humans) can be grouped into A, B, C, and D 
subfamilies. M14-A is the largest of these subfamilies and includes the human 
pancreatic digestive enzymes carboxypeptidase A1 (hCPA1), carboxypeptidase A2 
(hCPA2), and carboxypeptidase B (hCPB). These three enzymes are ∼35-kDa 
nonglycosylated proteins synthesized with a signal peptide and secreted as stable 
and inactive zymogens by the exocrine pancreas. A distinctive feature of these 
inactive zymogens is the presence of an extra ∼100 residue prosegment or 
prodomain that partially blocks their catalytic activity (5–9). After their secretion into 
the intestinal lumen, trypsin-promoted limited proteolysis generates active enzymes 
with ∼300 residues (10–12), which actively contribute to digestion of dietary proteins 
through the hydrolysis of C-t amino acids from peptides that are end products of 
digestive endopeptidases (13). The active forms of hCPA1, hCPA2, and hCPB 
display distinct but complementary substrate specificities. While hCPA1 and hCPA2 
show a higher preference for small aliphatic and bulky aromatic side chains, 
respectively (14), hCPB preferentially cleaves substrates with C-t basic amino acids 
(15–17). Although their combined action can release a wide range of amino acids 
that are absorbed in the intestinal tract, pancreatic MCPs are unable to release 
acidic C-t amino acids, such as Asp or Glu (13, 18, 19), even though these acidic 
residues are two of the most abundant amino acids in alimentary proteins (20–22). 
Human carboxypeptidase O (hCPO) is a recently described brush-border (BB) 
digestive enzyme that belongs to the M14-A subfamily of MCPs (18, 23). Enzymes of 
the small intestinal BB are responsible for the final stage of luminal digestion before 
absorption (19). Unlike pancreatic MCPs, hCPO has strict specificity toward acidic C-
t amino acids, a unique feature within the M14-A subfamily (18). In 2001, hCPO was 
first identified in a bioinformatic search for additional MCP members in the human 
genome (23). A decade later, the full-length CPO gene was shown to be present in a 
large number of vertebrate species, including mammals, birds, and fish (18). 
Whereas all other members of the M14-A subfamily are produced as inactive 
zymogens, hCPO does not contain a large prodomain and can be expressed as a 
constitutively active enzyme (18). hCPO is synthesized by cells of the intestinal 
epithelium, where it tethers to the apical plasma membrane through a covalently 
linked glycosylphosphatidylinositol (GPI) anchor (18). A large number of BB digestive 
enzymes have been found to contain anchors at the C-t, including alkaline 
phosphatase, trehalase, and dipeptidase 1, among others (24–26). In addition to GPI 
anchoring, posttranslational glycosylation is a feature common to BB digestive 
enzymes that presumably confers protection against proteolytic degradation (19). 
The glycosylation of hCPO probably accounts for its higher molecular mass (18). 
The activity of MCPs can be specifically regulated by proteinaceous inhibitors (2). 
During the past 50 y, a number of such MCP inhibitors have been isolated and 
characterized so far from potato and tomato (PCI and MCPI, respectively) (27–30), 
intestinal parasites Ascaris suum and Ascaris lumbricoides (ACI) (31, 32), the 
medical leech Hirudo medicinalis (LCI) (33), ticks Rhipicephalus 
bursa and Haemaphysalis longicornis (TCI and H1TCI, respectively) (34, 35), 
mammals (latexin) (36, 37) and, more recently, from the marine 
annelid Sabellastarte magnifica (SmCI) (38) and sea snail Nerita versicolor (NvCI) 
(39). Among them, the latter inhibitor NvCI was found to be the most potent inhibitor 
discovered for members of the M14-A subfamily, displaying equilibrium dissociation 
constants in the picomolar range (39). During the last decades, several crystal 
structures of pancreatic and extrapancreatic MCPs in complex with protein inhibitors 
have been obtained (29, 39–45). Although these protease-inhibitor structures shed 
light on functional mechanisms of MCPs and inhibitory binding properties, the 
detailed structural features that define the substrate specificity for C-t acidic amino 
acids remain still unexplored. 
In this study, we report the crystal structure of a soluble form of hCPO (hCPOΔC), 
unbound and in complex with NvCI, at 1.85-Å resolution; interestingly, both have 
been observed in the same asymmetric unit of a crystal. The structural analysis, 
functional characterization, and site-directed mutagenesis of hCPO reveal the 
molecular details by which this protease exhibits a preference toward acidic C-t 
amino acids and, hence, completes the analysis of the range of amino acid 
specificities found in digestive MCPs. In addition, structural changes in active site 
residues induced through NvCI binding and interactions between the protease and 
the inhibitor were investigated in detail and compared with those reported previously 
for other MCPs. We also report the substrate preference of hCPO for Glu over Asp 
residues, and describe the ability of this enzyme to cleave the C-t of endogenous 




Expression and Purification of hCPO Using Mammalian Cells. 
CPO is an N-glycosylated disulfide bond-containing protein with a GPI anchor 
located at the C-t (18). Such structural complexity represents a challenge for the 
expression and purification of the full-length hCPO in large amounts as soluble and 
functional enzyme for structural studies. Initial experiments showed that hCPO in 
which the C-t GPI signal sequence or the N-terminal (N-t) domain were removed 
retained full enzymatic activity (SI Appendix, Fig. S1). This suggested that the short 
N-t domain present within hCPO, with certain homology to the prodomain of related 
enzymes, did not function as an inhibitory prodomain, and that these truncated forms 
reflect the enzymatic functional properties of the wild-type enzyme (SI Appendix, Fig. 
S1E). 
To overcome the difficulties of its production, we cloned a C-t truncated form of 
hCPO (residues Tyr1-Trp329, according to the numbering for mature hCPO, and 
termed hereafter as hCPOΔC) into the pTriEx-7 expression vector, where the 
endogenous N-t signal sequence was exchanged by an IgM exporting signal 
sequence followed by an N-t Strep-tag II fusion protein tag (Fig. 1A). The hCPOΔC–
pTriEx-7 construct was transfected into HEK293 F mammalian cells for transient 
expression, leading to the secretion of the soluble recombinant protein into the 
culture media. At 9 d posttransfection, hCPOΔC was purified from the supernatant 
by a combination of three chromatographic steps (see Fig. 1B and SI Appendix, SI 
Materials and Methods for more details). Fig. 1C shows the SDS/PAGE analysis of 
the eluted samples after the different purification steps. After purification, hCPOΔC 
could be easily visualized on SDS/PAGE by Coomassie blue staining as a single 
broad band of ∼50 kDa. The identity and purity of the recombinant protein was 
additionally assessed by both size-exclusion chromatography and MALDI-TOF 
analysis, confirming its high purity and molecular mass of about 48.7 kDa (Fig. 
1 D and E). The observed molecular mass of purified hCPOΔC is about ∼20% 
higher than its predicted molecular mass of 40.8 kDa. Digestion of the purified 
recombinant protein with PNGase F confirmed that the molecular size discrepancy is 
a consequence of N-glycosylation, which is in agreement with a previous report (18). 
To investigate whether hCPOΔC behaves as a functional carboxypeptidase, we 
determined the kinetic parameters for the purified hCPOΔC using the colorimetric 
substrate 3-(2-furyl)acryloyl-Glu-Glu-OH (FA-EE) at pH 7.5 (see SI Appendix, SI 
Materials and Methods for more details). The resultant kinetic parameters (SI 
Appendix, Table S1) were comparable to those obtained previously for the full-length 







Fig. 1. Expression and purification of hCPOΔC. (A) Comparison of the domain structures of pancreatic 
MCPs (hCPA1, hCPA2, and hCPB) with hCPO and hCPOΔC. The latter corresponds to a C-t truncated 
form of hCPO that lacks the C-t tail and, therefore, the GPI membrane anchor. To improve protein 
expression and facilitate its purification, the endogenous N-t signal sequence (SP, in hCPO) of 
hCPOΔC was exchanged for an IgM signal sequence (IgM) plus an N-t Strep-tag II fusion protein tag 
(Strep-tag II). The tag was incorporated immediately before the N-t domain (Nt-domain). (B) 
Schematic diagram of the strategy followed for expression and purification of hCPOΔC. Protein 
expression was performed by transient transfection of HEK293 F mammalian cells grown in 
suspension. Medium was collected after 9-d incubation and the recombinant protein purified in 
three steps: 1) hydrophobic interaction chromatography using a Butyl 650-M resin, 2) affinity 
chromatography using anti–Strep-tag II resin, and 3) size-exclusion chromatography. (C) Coomassie-
stained SDS/PAGE showing purity of hCPOΔC in the expression medium (E.M) and after each 
purification step (1, 2 or 3). (D) Representative size-exclusion chromatography and (E) MALDI-TOF 
MS of the purified hCPOΔC. 
 
 
hCPOΔC Is Inhibited by a Wide Range of MCP Proteinaceous Inhibitors. 
Inhibition kinetic constants (Ki) for hCPOΔC toward different proteinaceous MCPs 
inhibitors (PCI, LCI, TCI, ACI, and NvCI) were determined at pH 7.5. The results of 
such kinetics analyses are summarized in Table 1. As expected, all tested MCP 
proteinaceous inhibitors, except for NvCI, inhibit hCPOΔC with Ki values in the 
nanomolar range (PCI 3.2 ± 0.6 nM, LCI 12.8 ± 3.1 nM, TCI 16.7 ± 3.1 nM, and ACI 
43.6 ± 6.3 nM), which are comparable to other members of the M14-A subfamily, 
such as hCPA1, hCPA2, and hCPB (28, 33, 34, 42). 
 
Table 1. Inhibitory constants (Ki) for different proteinaceous inhibitors against hCPOΔC 
 
 
Interestingly, NvCI, which was recently reported as the strongest inhibitor discovered 
so far for some members of the M14-A subfamily (39), weakly inhibited hCPOΔC, 
showing a much higher Ki value (Table 1). In the Michaelis–Menten kinetic analysis 
(SI Appendix, Fig. S2), NvCI displays a typical competitive inhibition behavior toward 
hCPOΔC, with a Ki value of 3.8 ± 0.5 µM (Table 1). Preincubation of NvCI with the 
enzyme for various periods of time did not affect its inhibitory activity, suggesting that 
NvCI behaves as a fast binding and stable inhibitor of hCPOΔC. 
Crystal Structure of hCPOΔC in Complex with NvCI. 
After exploring a wide variety of protein combinations and crystallization conditions, 
crystals of hCPOΔC were only grown in complex with NvCI after incubation at 18 °C 
for several weeks. The complex of hCPOΔC with NvCI was formed in the 
crystallization drop by mixing the enzyme and the inhibitor in a molar ratio of 1:0.5 
(hCPOΔC:NvCI). Crystals of hCPOΔC-NvCI belonged to the monoclinic space group 
C2 and diffracted beyond 1.85 Å resolution. The structure of the complex was solved 
by molecular replacement using hCPA4 as a starting model (PDB ID code 2PCU) 
(46) and was refined to a final R-factor and R-free of 18.6 and 20.8, respectively (SI 
Appendix, Table S2). 
The crystals of the hCPOΔC–NvCI complex contained two hCPOΔC molecules in 
the asymmetric unit (Fig. 2A), chains A and B, but only one had NvCI bound. Each 
hCPOΔC polypeptide chain (chain A bound to NvCI and chain B unbound) could be 
clearly and completely traced in the electron density maps, from Glu23 to Trp329 
(according to the numbering for mature hCPO without the signal peptide). In the 
initial unbiased electron density maps, NvCI (chain C) was clearly observed bound 
only to one of the two hCPOΔC molecules of the asymmetric unit, and could be 
completely traced from Phe1 to Ala53 (Fig. 2A). Despite the presence of two 
hCPOΔC molecules in the asymmetric unit, interface analysis with the PDBePISA 
software (47) and previous results obtained by gel-filtration chromatography indicate 






Fig. 2. Three-dimensional structure of hCPOΔC in complex with NvCI. (A) The two monomers of 
hCPOΔC in the asymmetric unit (chains A and B, shown in blue and magenta, respectively) are 
stacked forming a homodimeric quaternary crystal structure. In contrast to chain B, chain A has a 
clear electron density in the active site region that accounts for a NvCI molecule (NvCI, in orange). In 
chain A, three N-glycan sites are indicated by an electron density of NAG at the Asn154, Asn167, and 
Asn231 consensus glycosylation sites as shown by the green stick models. In contrast, the electron 
density around the NAG at Asn154 in chain B is less complete, missing the N-glycan located in this 
position. (B) Two views of the 3D structure of recombinant hCPOΔC shown in ribbon representation. 
The catalytic carboxypeptidase domain of hCPOΔC displays a typical MCP-fold composed of eight α-
helices and a mixed eight-stranded β-sheet that forms a globular α/β protein. The α-helices (α1–α8) 
and β-strands (β1–β8) are shown in blue and magenta, respectively. The three N-glycosylated 
residues (Asn154, Asn167, and Asn231) are depicted as green stick models. (C) Surface 
representation of hCPOΔC from chain A (blue model) bound with NvCI in a ribbon representation 
(orange model). (D) Surface representation of hCPOΔC from chain B in its unbound form. 
In C and D a magnification of the catalytic site cleft is shown. (E) Close-up view in stick 
representation of the active site of hCPOΔC in the absence (magenta) or in the presence of NvCI 
(blue). For clarity, only the last two C-t residues of NvCI (Tyr52 and Ala53) that enter the active site 
of hCPOΔC are shown in orange and superimposed with the final electron density corresponding to a 
1.85-Å resolution F0–Fc Fourier map contoured at 1σ (mesh in cyan). The major change caused by the 
presence of NvCI in the active site is observed in the side chain of Tyr268, which rotates around its 
1× angle and displaces the hydroxyl group 10.8 Å to further close the active site pocket. Other minor 
rearrangements at the active site are also observed, including minor movements of the side chains 
of Arg146, Arg164, Leu223, Ser270, Arg275, and Thr288. Residues are numbered according to the 
mature hCPO sequence without the signal peptide (Tyr1-Trp329). In B–E the catalytic zinc atom is 




Electron density maps clearly define three different N-linked glycosylation sites in the 
hCPOΔC crystal structure at Asn154, Asn167, and Asn231 in chain A; and Asn167 
and Asn231 in chain B. In all cases the maps are well defined only for the N-
acetylglucosamine (NAG) residue of the glycosyl moiety. Interestingly, NAG linked to 
Asn154 that is only observed in chain A is localized at contact distance to the NvCI 
inhibitor and displays the lowest B-factor of all observed NAGs in the structure (Fig. 
2B). 
The two different molecules of hCPOΔC in the asymmetric unit of the crystal, 
substrate-free (chain B) and complexed with the substrate-like inhibitor (chain A), 
allow us to compare the structural changes of residues forming the active-site pocket 
in closely similar environments (Fig. 2 C and D). The average main-chain rmsd 
deviation between chain A and chain B is 0.33 Å, increasing to 1.85 Å in the loop 
region between β-sheet β7 and α-helix α7 that contain the active site residue Tyr268 
(Tyr248 in bCPA), which has been extensively reported in several MCP complex 
structures to move from the “up” to the “down” conformation upon binding of 
substrates or inhibitors (Fig. 2E) (12, 39, 42, 45). It marks the major structural 
difference observed between the “open” and “closed” conformations seen in chain B 
and chain A of hCPOΔC. 
Structure of hCPOΔC. 
The structure of the carboxypeptidase domain of hCPOΔC shows the classic 
compact α/β-hydrolase fold of the M14 family of MCPs, which is formed by a central 
twisted eight-stranded mixed β-sheet (strands β1 to β8) flanked by eight α-helices 
(Fig. 2B and SI Appendix, Fig. S3A). Structural alignment of the carboxypeptidase 
domains of hCPOΔC and pancreatic MCPs hCPA1, hCPA2, and hCPB confirms the 
structural similarities within the M14-A subfamily, displaying main-chain rmsd 
deviations of 0.85 Å for 299 aligned residues with a 40% sequence identity for 
hCPA1, of 0.83 Å for 297 aligned residues with a 39% sequence identity for hCPA2, 
and of 0.83 Å for 300 aligned residues with a 47% sequence identity for hCPB (SI 
Appendix, Fig. S3). All relevant M14 MCPs active site residues are shared by 
hCPOΔC and located in analogous positions, including: the Zn2+ coordinating 
residues His88, Glu91, and His216 (His69, Glu72, and His196 in bCPA); the catalytic 
Arg146 and Glu290 (Arg127 and Glu270 in bCPA); the C-t carboxylate substrate-
binding Asn163 and Arg164 (Asn144 and Arg145 in bCPA); and Tyr268 (Tyr248 in 
bCPA), in its alternative conformations in liganded and unliganded hCPOΔC 





Fig. 3. Structural features of the active site of hCPOΔC and comparison with the active sites of 
pancreatic MCPs. Detailed view of the active site groove of hCPOΔC in (A) the closed conformation 
observed in the complex with NvCI (chain A), and in (B) the open conformation observed in the 
substrate-free molecule (chain B). In A and B, the side chains of those residues important for 
catalysis and substrate binding are shown in stick representation (in blue and magenta, 
respectively), and shown together with the half-transparent surface (in gray). In both panels, 
residues were numbered according to the amino acid position in mature hCPO. The characteristic 
Arg275 amino acid that determines the substrate specificity for C-t acidic residues in hCPO is located 
at the bottom of the active site cleft. (C) Stereoview of the active site groove of hCPOΔC in the open 
conformation (blue sticks), superimposed with human hCPA1 (green sticks, PDB ID code 3FJU) (42). 
The same residues shown in A and B were labeled and numbered according to the reference bCPA 
nomenclature. For the sake of better visibility of Ile255, the side chain of Ser263 (Ile243 in bCPA) has 







A distinctive feature of hCPOΔC is its substrate-binding pocket, which endows it with 
the C-t processing specificity of Glu and Asp residues (18). This particular activity of 
hCPO depends on the presence of an arginine residue, Arg275, located at the 
bottom center of the substrate specificity pocket and which plays a central role by 
creating a positively charged surface optimal for interaction with amino acid side 
chains containing negatively charged carboxylate groups, such as glutamate or 
aspartate. Arg275 replaces Ile255 in hCPA1 and hCPA2, which prefer C-t aliphatic 
and aromatic amino acids, respectively, and Asp253 in hCPB, with a demonstrated 
specificity for C-t basic amino acids (Figs. 3C and 4). Only Pro C-t amino acids 
escape from the action of these enzymes; however, these are presumably cleaved 
by proline-hydrolyzing carboxypeptidases, such as angiotensin-converting enzyme 









Fig. 4. Characteristics of the binding pockets in digestive MCPs that determine the different 
substrate specificity. (A–D) Binding pockets of (A) hCPA1, (B) hCPA2, (C) hCPB, and (D) hCPO, 
displayed as a surface-rendered cavity. The electrostatic potential at the surface of the substrate-
binding pocket is represented as a color gradient from red (−60 KBT/ec) to white (0 KBT/ec) to blue 
(+60 KBT/ec). Atomic coordinates of hCPA1 (PDB ID code 3FJU) (42), hCPA2 (PDB ID code 1DTD) (43), 
and hCPB (PDB ID code 1ZLI) (45) were obtained from the PDB. (E–H) Schematic representations of 
the substrate-binding pockets shown in A–D. (E) In hCPA1 a hydrophobic S1′ subsite binds small 
aliphatic residues such as Leu, Val, or Ala better. (F) In hCPA2 the presence of a much larger 
hydrophobic pocket than hCPA1 determines its stronger preference for bulkier hydrophobic amino 
acids such as Phe, Tyr, or Trp. However, in both cases, the specificity for hydrophobic/aliphatic 
amino acids is determined due to the presence of an Ile residue (I255, according to numbering in 
mature active hCPA1 and hCPA2) found in the base of a deep hydrophobic pocket. (G) hCPB 
specificity for basic residues is due to a negatively charged Asp residue (D253, according to 
numbering in mature active hCPB) located in the base of the binding pocket. (H) In hCPO the side 
chain of an Arg residue in position 275 (R275) is located in the base of the active site in an equivalent 
position to the I255 found in hCPA and hCPA2, and to D253 of hCPB. This contributes to its specificity 




To confirm the role of Arg275 for the substrate specificity of the enzyme, the 
positively charged Arg275 was replaced, in protein recombinant mutants, either by 
Asp (the hCPOΔC R275D mutant, in homology to hCPB) or by a small aliphatic 
residue Ala (the hCPOΔC R275A mutant). The substitution of the positive residue 
Arg275 for Asp drastically reduced the activity of the enzyme for the substrate FA-EE 
(Table 2 and SI Appendix, Fig. S4) and reversed the enzyme cleaving specificity: 
from glutamic to lysine C-t residues. As shown in Table 2, the Kcat/KM value of 
hCPOΔC R275D for 3-(2-furyl)acryloyl-Ala-Lys-OH (FA-AK) is 0.041 ± 0.004 
µM−1 s−1 and is similar to CPB with 0.058 ± 0.018 µM−1 s−1 (Table 2). An earlier 
converse experiment by mutations of CPB (48) is in accord with these findings. The 
substitution by mutagenesis for Ala in the same position in hCPOΔC R275A reduced 
the activity of the enzyme toward FA-EE and led to a protease with preference for C-
t hydrophobic residues, as shown by a Kcat/KM of 0.039 ± 0.006 µM
−1 s−1 (Table 
2 and SI Appendix, Fig. S4), comparable to type-A carboxypeptidase. It is 
remarkable that the substrate specificity of the different types of carboxypeptidases 
is determined by a single residue at the core of the specific pocket. 
 
Table 2.Effect of mutations of Arg275 on the substrate specificity of hCPO 
 
 
Besides the major role of Arg275, the cavity of the substrate-binding pocket in hCPO 
is also formed by Leu223, Gly227, Ser263, Leu267, Ser273, and Thr288 (Fig. 
3 A and B and SI Appendix, Fig. S3B). These residues are mostly conserved in 
CPA- and CPB-like MCPs, shaping a cavity with enough space to accommodate all 
types of side chains of C-t residues. For example, Leu223 in hCPO is substituted by 
either Met or Ile in hCPAs and hCPB, respectively; and Gly227, Ser263, Ser273, and 
Thr288 in hCPO are substituted by analogous residues in hCPA1, hCPA2, and 
hCPB (Fig. 3C and SI Appendix, Fig. S3B). 
 
Structural Determinants of hCPOΔC Inhibition by NvCI. 
Only one of the hCPOΔC molecules in the asymmetric unit establishes a complex 
with NvCI, leaving the second hCPOΔC molecule unbound. This feature may be 
enforced by favorable crystal contacts and by the weak binding of NvCI to hCPO, as 
shown by an inhibition constant (Ki) value in the micromolar range (Table 1). 
Noteworthy, NvCI interacts extensively with the hCPO surface, with a total contact 
area of 1,734 A2, which is comparable to the previous structure of NvCI in complex 
with hCPA4 (39). NvCI is basically formed by a central two-stranded antiparallel β-
sheet stabilized by three disulphide bonds (SI Appendix, Fig. S5A). The inhibitory 
mechanism is based on a competitive substrate-like interaction of its C-t tail, formed 
by Tyr52 and Ala53, with the active site of hCPO, occluding the active site subsites 
S2 and S1, respectively, as occurs in the other known carboxypeptidase 
proteinaceous inhibitors (SI Appendix, Fig. S5E). The C-t tail of NvCI constitutes the 
“primary” binding region, with the C-t carboxylate group of Ala53 coordinating the 
zinc atom in a bidentate form (Fig. 2E and SI Appendix, Fig. S5B and Table S3). 
Other relevant interactions of this primary binding region include a hydrogen bond 
between the amino group of Ala53 and the hydroxyl oxygen of Tyr268, which is 
involved in the aforementioned “up” to “down” conformational change of Tyr268 in 
the hCPOΔC structure (SI Appendix, Fig. S5B and Table S3), and the hydrogen 
bonds between the carbonyl oxygen of Tyr52 with side chains of Arg90 and Arg146 
(SI Appendix, Fig. S5B and Table S3). 
The interaction network of the primary binding region of NvCI in complex with 
hCPOΔC is quite similar to the previous complex with hCPA4 (39) and differences 
are mostly observed in contacts of the extended “secondary” binding region. The 
secondary binding region between NvCI and hCPOΔC is composed of contacts 
distant from the active site groove (SI Appendix, Fig. S5 C and D) and seems to 
determine the inhibitory capabilities toward MCPs (39). 
NvCI displays micromolar Ki values for hCPOΔC, in contrast to the 
picomolar Ki values shown for hCPA4 (39). Whereas in NvCI the primary binding 
region between hCPA4 and hCPOΔC are quite similar, several changes are 
observed in the secondary binding region between both complexes (SI Appendix, 
Fig. S6 A and B). Perhaps the most significant difference in the hCPOΔC complex is 
the loss of hydrogen bonds between the amino groups of Cys51 and Tyr52 with the 
side chain of Gln182 (Glu163 in hCPA4), which was suggested to be a relevant 
interaction responsible for the low Ki value displayed toward hCPA4 (SI Appendix, 
Fig. S6 B and C) (39). Other differences include the loss of main-chain hydrogen 
bond contacts from Ile10 and Asn11, and from side chains of Lys28 and Gln39 (SI 
Appendix, Fig. S6 B, D, and E and Table S3). However, in the complex between 
NvCI and hCPOΔC, a few new contacts are observed, such as the side chain of 
Asn32 with the main-chain oxygen of Gly155, and of particular interest, the contact 
between Asp33 with the NAG-linked Asn154, contacting both the amino acid side 
chains and the sugar moieties (SI Appendix, Fig. S6D and Table S3). 
hCPOΔC Cleaves C-t Acidic Residues, with a Clear Preference for Glu over 
Asp. 
To evaluate the substrate preference of hCPOΔC for cleavage of Glu vs. Asp, we 
examined the activity of the purified enzyme toward a synthetic peptide with a Glu or 
Asp in the C-t position (ARLSQKFPKAE or ARLSQKFPKAD, respectively). Both 
synthetic peptides were incubated with purified hCPOΔC and reactions analyzed by 
MALDI-TOF MS (SI Appendix, Fig. S7 A and B). To obtain semiquantitative 
information about the cleavage, different incubation times for each peptide were 
analyzed. When tested with the synthetic peptide with a C-t Glu, the enzyme 
completely cleaved off the latter residue after 15 min of incubation (SI Appendix, Fig. 
S7A). Similarly, the enzyme was also able to cleave off the peptide containing a C-t 
Asp, but longer times were needed (>30 min) to observe a complete decrease in the 
peak intensity corresponding to the peptide substrate (SI Appendix, Fig. S7B). 
hCPOΔC was not able to process other peptides, such as Met-enkephalin peptides 
with C-t hydrophobic (Phe) or basic residues (Arg or Lys), even after much longer 
incubation times (SI Appendix, Fig. S7 C–E). 
These results demonstrated a clear preference of the enzyme for Glu over Asp. 
Modeling analysis of either Asp or Glu substrate inside the substrate-binding pocket 
in our hCPOΔC structure, based on a previous model structure of hCPA4 in complex 
with a cleaved hexapeptide substrate (46), suggests that hCPO’s preference for C-t 
Glu substrates is facilitated by the contact between the carboxylate group of the 
substrate Glu with the side chain of Arg275 (SI Appendix, Fig. S8). 
C-t Proteolysis of hEGF by hCPOΔC. 
Human EGF (hEGF) is an important trophic factor produced mainly by salivary 
glands and the Brunner’s duodenal glands as a 53-amino acids peptide (EGF1–53), 
which is secreted in large amounts to the digestive tract (49⇓⇓–52). Although EGF1–
53 is generally considered to be the “mature” form of EGF in humans, other 
circulating C-t truncated forms have been observed (EGF1–52, EGF1–51, EGF1–50, and 
so on), as a result of partial cleavage by unknown proteases from the gastrointestinal 
lumen (53⇓⇓⇓⇓⇓–59). These relatively small changes in the C-t region of the 
molecule result in a marked effect on the EGF receptor binding (60, 61), thus 
affecting its biological activity (62). 
To determine whether hCPO processes EGF, we incubated the full-length EGF 
(EGF1–53) with both CPA and CPB in the absence or in the presence of purified 
hCPOΔC (see SI Appendix, SI Materials and Methods for more details). Fig. 
5A depicts some points of the time course of EGF1–53 degradation as followed by 
MALDI-TOF MS analysis. The combination of CPA and CPB was rapidly able to 
excise Arg53 and Leu52 from EGF1–53 (red spectra, Fig. 5A). The presence of a Glu 
in position 51 of the EGF molecule limited the trimming action of CPA and CPB, 
which is to proceed further to generate smaller EGF forms (such as EGF1–50 or other 
shorter forms). In contrast, the addition of hCPOΔC to the reaction mixtures 
enhanced the C-t truncation of EGF, by cleaving Glu51 from EGF1–51 (blue 
spectra, Fig. 5). These results reveal the ability of hCPO to digest not only synthetic 
and small peptides, but also C-t residues of larger proteins and peptides, suggesting 
a potential role for this enzyme in the regulation of peptidic growth factors and 
bioactive peptides circulating in the BB of the intestinal tract. 
 
Fig. 5.Substrate specificity of hCPOΔC in the C-t proteolytic cleavage of synthetic peptides and hEGF. 
(A) Representative MALDI-TOF MS spectra of full-length recombinant human EGF (EGF1–53) incubated 
for different times at 37 °C with 30 nM bCPA and 50 nM pCPB in the absence (red spectra) or in the 
presence (blue spectra) of 30 nM hCPOΔC. (B) Ribbon representation and amino acid sequence of 
human EGF. The C-t peptide bonds cleaved by the proteolytic action of bCPA, pCPB, and hCPOΔC are 
indicated below the sequence. The peptide bond that is mainly cleaved by hCPOΔC is indicated 
above the sequence with scissors. Note that the full-length recombinant human EGF used in the 
experiment contains the EGF1−53 sequence plus an additional N-t Met residue. Accordingly, the 
monoisotopic molecular masses are: EGF1−53 = 6,348.77 Da; EGF1−51 = 6,078.85 Da; EGF1−48 = 5,577.32 
Da; EGF1−47 = 5,449.15 Da. Atomic coordinates of hEGF (PDB ID code 1IVO) were obtained from the 









For many decades, the pancreatic enzymes hCPA1, hCPA2, and hCPB were 
considered the only digestive carboxypeptidases of the M14 family present in 
humans. However, these enzymes are only able to release a fraction of all C-t 
residues present in dietary proteins. The discovery of the distinctive activity of hCPO 
for C-t acidic residues explains the cleavage of almost all types of amino acids and 
the nearly complete C-t degradation of proteins and peptides in the digestive tract. In 
this work we describe the structural details responsible for the specificity of hCPO for 
C-t Glu and Asp residues, and identify Arg275 located at the center of the substrate-
binding pocket of the active site as the essential determinant. Structural comparison 
of the substrate-binding pockets of hCPA1, hCPA2, hCPB, and hCPO, the whole 
complement of digestive MCPs, reveals the essential roles of the equivalent residues 
in these enzymes in determining their cleavage specificities 
Site-specific changes of Arg275 in hCPO to Asp and Ala reverses the specificity of 
these mutants, which cleave C-t basic and apolar residues, respectively, resembling 
the specificity of hCPB and hCPA1/2. In the case of hCPA1 and hCPA2, Ile255 
provides the appropriate environment for binding aliphatic and aromatic substrate 
residues, whereas Asp253 endows hCPB with specificity for basic substrate residues 
(Fig. 4). Biochemical and kinetic analyses using hCPO also indicate a clear 
preference for processing C-t Glu over Asp substrates. Modeling suggests indeed a 
better accommodation of the longer side chain of Glu in the substrate-binding pocket 
by a salt linkage with Arg275. Finally, in addition to its role in the digestion of dietary 
peptides at the apical membrane of intestinal cells, hCPO accelerates C-t trimming 
of human EGF in vitro and might therefore have regulatory functions in the intestine. 
Materials and Methods 
A detailed description of procedures is provided in SI Appendix, SI Materials and 
Methods. Briefly, to facilitate production and crystallization, a recombinant C-t 
truncated form of hCPO (hCPOΔC) was produced and used instead of the intact/full 
form. Thus, it was overexpressed in HEK293 F mammalian cells by using the pTriEx-
7 vector, which includes an N-t IgM exporting signal sequence and the Strep-Tag II 
affinity tag. The resultant recombinant protein hCPOΔC was purified to homogeneity 
by combining three chromatographic steps: hydrophobic interaction chromatography, 
affinity chromatography, and gel filtration. The catalytic activity of the purified 
hCPOΔC was tested against the typical colorimetric substrates FA-EE, FA-AK, and 
3-(2-furyl)acryloyl-Phe-Phe-OH (FA-FF), and toward synthetic peptides and hEGF by 
MALDI-TOF MS. The same production procedure and assays apply to the mutants 
hCPOΔC R275D and hCPOΔC R275A. In addition, the inhibitory activities of a set of 
MCPs proteinaceous inhibitors were determined. Crystals of the NvCI–hCPOΔC 
complex were obtained by the sitting-drop vapor diffusion method by incubating a 
mix of the protease and the inhibitor (in a molar ratio of 1:0.5). The structure was 
solved by molecular replacement using the coordinates from hCPA4 in complex with 
NvCI as searching model. Crystallographic data are summarized in SI Appendix, SI 
Materials and Methods and Table S2. 
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